9c99946058
- Source: inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
3.6 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | processed_by | processed_date | priority | tags | extraction_model | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Semaglutide for OUD Phase 2 Trial Protocol Published (Addiction Science & Clinical Practice, 2025) | Grigson PS et al. (Penn State / NIH) | https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-025-00618-2 | 2025-05-01 | health | trial-protocol | processed | vida | 2026-04-25 | low |
|
anthropic/claude-sonnet-4.5 |
Content
Published in Addiction Science & Clinical Practice (BioMed Central). PMID 40502777 (very high PMID — published mid-2025).
Trial: NCT06548490
- Phase 2, double-blind, placebo-controlled RCT
- Principal investigator: Grigson PS (Penn State)
- n = 200 participants
- Population: Treatment-refractory OUD — patients already enrolled in MOUD (buprenorphine or methadone) programs who continue using illicit opioids
- Sites: 3 US sites
- Enrollment status: First participant enrolled January 27, 2025; sites fully open June 2025
- Expected completion: November 2026
Primary endpoint: Opioid abstinence measured by urine drug screens and self-report over 12 weeks
Rationale:
- Observational studies show GLP-1 RAs associated with lower opioid overdose risk
- Animal models: GLP-1 RAs reduce opioid self-administration
- Qeadan 2025 (Addiction journal): 40% lower overdose rate (IRR 0.60) in real-world cohort
- Mechanism: shared VTA dopamine reward circuit with metabolic/alcohol applications
- Semaglutide is the agent being tested
Gap this fills: No completed Phase 2 RCT for GLP-1 + OUD as of April 2026. This is the definitive human trial that will either confirm or refute the animal/observational signal.
Agent Notes
Why this matters: Status update on the thread from Session 26-27. The protocol is published and the trial is actively enrolling (first participant January 2025). November 2026 completion means results available late 2026 / early 2027 at the earliest (analysis takes time after completion).
What surprised me: Nothing new here — this confirms the information from Sessions 26-27. The protocol is now formally published (not just registered), which adds credibility to the research program but doesn't change the evidence status.
What I expected but didn't find: Results. The trial is still running. No interim analysis published.
KB connections:
- Directly extends: Sessions 26-27 GLP-1 reward circuit thread
- Connects to: GLP-1 receptor agonists are the largest therapeutic category launch... — OUD application would significantly extend the therapeutic scope
- If results are positive, would extend the "shared VTA dopamine mechanism" claim from AUD to OUD
- Potentially relevant to addiction epidemiology / deaths of despair claims
Extraction hints:
- Update existing queue entry if one exists (none found — this is new)
- The protocol publication is evidence that the research is active and properly registered — raises credibility of the overall OUD signal
- Do NOT extract a claim from the protocol itself — extract only from results when published
- FLAG for monitoring: November 2026 completion → results likely Q1-Q2 2027
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 reward circuit thread (Session 26-27 musing candidates) WHY ARCHIVED: Status update on the definitive OUD trial. Confirms enrollment active, timeline (November 2026 completion). No results yet. EXTRACTION HINT: No claim extraction from protocol. Monitor for results in late 2026/early 2027. Flag as a session monitoring thread — revisit when results publish.